| Code | Display |
| 000 |
正常 |
| 001 |
AML with RUNX1-RUNX1T1 |
| 002 |
AML with CBFB-MYH11 |
| 003 |
Acute promyelocytic leukemia with PML-RARA |
| 004 |
AML with KMT2A-MLLT3 |
| 005 |
AML with DEK-NUP214 |
| 006 |
AML with GATA2, MECOM |
| 007 |
AML(megakaryoblastic) with RBM15-MKL1 |
| 008 |
AML with mutated NPM1 |
| 009 |
AML with biallelic mutation of CEBPA |
| 010 |
AML with mutated FLT3/ITD |
| 011 |
AML with mutated FLT3/TKD |
| 012 |
AML with MLL-PTD (partial tandem duplication) |
| 013 |
AML with BCR-ABL1 |
| 021 |
B lymphoblastic leukemia/lymphoma with BCR-ABL1 |
| 022 |
B-lymphoblastic leukemia/lymphoma with KMT2A-rearranged |
| 023 |
B-lymphoblastic leukemia/lymphoma with ETV6-RUNX1 (TEL-AML1) |
| 024 |
B-lymphoblastic leukemia/lymphoma with IGH/IL3 |
| 025 |
B-lymphoblastic leukemia/lymphoma with TCF3-PBX1 (E2A-PBX1) |
| 041 |
Mixed phenotype acute leukemia with BCR-ABL1 |
| 042 |
Mixed-phenotype acute leukemia with KMT2A-rearranged |
| 051 |
Chronic myelogenous leukemia BCR-ABL1 positive |
| 052 |
JAK2 V617F mutation |
| 053 |
Myeloid and lymphoid neoplasms with PDGFRA rearrangement |
| 054 |
Myeloid and lymphoid neoplasms with PDGFRB rearrangement |
| 055 |
Myeloid and lymphoid neoplasms with FGFR1 rearrangement |
| 090 |
(1) 一種異常，其他上述未列之分子檢驗異常 (2) 二種異常，其中一種非上述之分子檢驗異常 (3) 二種異常，二種皆非上述之分子檢驗異常 |
| 091 |
同時有兩種(含)以上上述之分子檢驗異常 |
| 092 |
同時有三種(含)以上分子檢驗異常 (1) 三種(含)以上異常，其中一種以上非上述之分子檢驗異常 (2)三種(含)以上異常，皆非上述之分子檢驗異常 |
| 8XX |
Molecular study after chemotherapy or immunotherapy or target therapy |
| 988 |
不適用。(1) ICD-O-3 M-9811-9837 (EXCEPT C42.0, 42.1, 42.4) |
| 998 |
有執行分子生物學檢查，但結果無法判斷 |
| 999 |
(1) 病歷未記載或不詳 (2) 未執行分子生物學檢查 |